[go: up one dir, main page]

PE20040569A1 - Uso de n-(indolcarbonil-)piperazinas como antagonistas de los receptores 5-ht2a - Google Patents

Uso de n-(indolcarbonil-)piperazinas como antagonistas de los receptores 5-ht2a

Info

Publication number
PE20040569A1
PE20040569A1 PE2003000995A PE2003000995A PE20040569A1 PE 20040569 A1 PE20040569 A1 PE 20040569A1 PE 2003000995 A PE2003000995 A PE 2003000995A PE 2003000995 A PE2003000995 A PE 2003000995A PE 20040569 A1 PE20040569 A1 PE 20040569A1
Authority
PE
Peru
Prior art keywords
well
piperazines
antagonists
indolcarbonyl
fluorophenethyl
Prior art date
Application number
PE2003000995A
Other languages
English (en)
Inventor
Gerd Bartoszyk
Amsterdam Christoph Van
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32010223&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20040569(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PE20040569A1 publication Critical patent/PE20040569A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

SE REFIERE AL USO DE DERIVADOS DE N-(INDOLCARBONIL-) PIPERAZINAS COMO ANTAGONISTAS DE LOS RECEPTORES 5-HT2 EN ESPECIAL DEL SUBTIPO 5-HT2A DONDE LOS COMPUESTOS PREFERIDOS SON: (3-AMINOCARBONIL-1H-INDOL-7-IL)-[4-(4-FLUOROFENETIL)-PIPERAZIN-1-IL]-METANONA, (3-CIAN-1H-INDOL-7-IL)-[4-(4-FLUOROFENETIL)-PIPERAZIN-1-IL]-METANONA, ENTRE OTROS. ASI COMO SUS SALES Y SOLVATOS PARA SU UTILIZACION EN LA PEPRARACION DE UN MEDICAMENTO PARA PROLONGAR EL SUENO REM, ASI COMO TAMBIEN EL SUENO NO REM, PARA EL TRATAMIENTO DE TRANSTORNOS DE CONCILIACION Y CONTINUIDAD DEL SUENO, ASI COMO UN DESPERTAR ANTICIPADO EN LAS MANANAS, TAMBIEN SE REFIERE A UNA PREPARACION FARMACEUTICA QUE CONTIENE EL INGREDIENTE ACTIVO ASI COMO EVENTUALMENTE VEHICULOS Y/O EXCIPIENTES, ESTOS COMPUESTOS PUEDEN ADMINISTRARSE CON OTROS INGREDIENTES ACTIVOS COMO EL GRUPO DE LOS SOMNIFEROS
PE2003000995A 2002-10-04 2003-10-01 Uso de n-(indolcarbonil-)piperazinas como antagonistas de los receptores 5-ht2a PE20040569A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10246357A DE10246357A1 (de) 2002-10-04 2002-10-04 Verwendung von 5-HT2Rezeptorantagonisten

Publications (1)

Publication Number Publication Date
PE20040569A1 true PE20040569A1 (es) 2004-08-30

Family

ID=32010223

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000995A PE20040569A1 (es) 2002-10-04 2003-10-01 Uso de n-(indolcarbonil-)piperazinas como antagonistas de los receptores 5-ht2a

Country Status (18)

Country Link
US (1) US20060040951A1 (es)
EP (1) EP1545531A1 (es)
JP (1) JP2006503870A (es)
KR (1) KR20050054996A (es)
CN (1) CN1688309A (es)
AR (1) AR041476A1 (es)
AU (1) AU2003283237A1 (es)
BR (1) BR0314945A (es)
CA (1) CA2501082A1 (es)
DE (1) DE10246357A1 (es)
MX (1) MXPA05003437A (es)
PE (1) PE20040569A1 (es)
PL (1) PL374077A1 (es)
RU (1) RU2005113712A (es)
TW (1) TW200410691A (es)
UA (1) UA79993C2 (es)
WO (1) WO2004032932A1 (es)
ZA (1) ZA200503520B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004047517A1 (de) * 2004-09-28 2006-03-30 Merck Patent Gmbh Neuartige Kristallform von (3-Cyan-1H-indol-7-yl)-[4-(4-fluorphenethyl)-piperazin-1-yl]-methanon, Hydrochlorid

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865939A (en) * 1973-02-23 1975-02-11 Procter & Gamble Edible oils having hypocholesterolemic properties
DE3119383A1 (de) * 1981-05-15 1982-12-02 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von feinverteilten, pulverfoermigen carotinodpraeparaten
US5244887A (en) * 1992-02-14 1993-09-14 Straub Carl D Stanols to reduce cholesterol absorption from foods and methods of preparation and use thereof
PT1148793E (pt) * 1999-02-03 2003-12-31 Forbes Medi Tech Inc Metodo para a preparacao de microparticulas de fitoesterois ou fitoestanois
DE19934433A1 (de) * 1999-07-22 2001-01-25 Merck Patent Gmbh N-(Indolcarbonyl-)piperazinderivate
US6391370B1 (en) * 1999-11-12 2002-05-21 Kraft Foods, Inc. Micromilling plant sterols and emulsifiers
US6576285B1 (en) * 2000-11-14 2003-06-10 Sunpure Ltd. Cholesterol lowering beverage
DE10102944A1 (de) * 2001-01-23 2002-07-25 Merck Patent Gmbh Verfahren zur Herstellung von (3-Cyan-1H-indol-7-yl)-[4-(4-fluorphenethyl)-piperazin-1-yl]-methanon und dessen Salzen
DE10157673A1 (de) * 2001-11-24 2003-06-05 Merck Patent Gmbh Verwendung von N-(Indolcarbonyl-)piperazinderivaten

Also Published As

Publication number Publication date
AU2003283237A1 (en) 2004-05-04
TW200410691A (en) 2004-07-01
RU2005113712A (ru) 2005-11-20
BR0314945A (pt) 2005-08-02
CN1688309A (zh) 2005-10-26
KR20050054996A (ko) 2005-06-10
PL374077A1 (en) 2005-09-19
DE10246357A1 (de) 2004-04-15
AR041476A1 (es) 2005-05-18
UA79993C2 (en) 2007-08-10
EP1545531A1 (de) 2005-06-29
WO2004032932A1 (de) 2004-04-22
JP2006503870A (ja) 2006-02-02
MXPA05003437A (es) 2005-07-05
ZA200503520B (en) 2006-02-22
US20060040951A1 (en) 2006-02-23
CA2501082A1 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
PA8587101A1 (es) Nuevos derivados de dihidropirimido [4,5-d] pirimidinona sustituida por amiino, fabricacion y uso de los mismos como agentes farmaceuticos
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
UY28231A1 (es) Metodos y composiciones farmacéuticas para la obtención confiable de niveles aceptables de testosterona en suero.
DK1526839T3 (da) Orale farmaceutiske former for flydende lægemidler med forbedret biotilgængelighed
AR020001A1 (es) COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO
BR0315547A (pt) Derivados de quinolina como antagonistas de crth2
NO20080670L (no) Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister
CU23423B7 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulación sanguínea
ATE390135T1 (de) Verfahren zur verwendung von und zusammensetzungen mit immunomodulatorischen verbindungen zur behandlung und versorgung von myelodysplastischen syndromen
CO2021006482A2 (es) Ureas cíclicas
UY26291A1 (es) Compuestos químicos xxii
AR026916A1 (es) Combinaciones farmaceuticas y su uso en el tratamiento de desordenes gastrointestinales
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
ES2052603T3 (es) Derivados de bencimidazol, procedimiento para su produccion y composicion farmaceutica que los contienen.
EA200300183A1 (ru) Новое сочетание агониста (5-th2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции
BRPI0511224A (pt) método para preparar uma composição contendo antagonistas de opióides, produto contendo antagonistas de opióides, composição contendo antagonistas de opióides, formulação de dosagem injetável, kit, método para prevenir ou tratar um efeito colateral associado com um opióide num paciente, e para tratar ou impedir dor num paciente
AR035603A1 (es) Derivados de piperazina, composicion farmaceutica que los comprende y el uso de los mismos para la fabricacion de un medicamento como agentes serotonergicos
AR029373A1 (es) Metodo para el tratamiento de migranas, utilizando compuestos antagonistas selectivos de los receptores iglur5, uso de dichos compuestos antagonistas selectivos en la manufactura de medicamentos para el tratamiento de migranas y dichos compuestos antagonistas
ATE364044T1 (de) 5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit
EE200100104A (et) 5-HT4 agonisti või antagonisti uus peroraalne ravimvorm
PE20040973A1 (es) Composiciones de anti-histaminicos, descongestivos y drogas anti-inflamatorias no esteroidales
BRPI0413013A (pt) composto, seus sais, solvatos, e derivados farmaceuticamente funcionais, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou distúrbios, e de doenças
AR046036A1 (es) Composiciones de risedronato y metodos para su uso

Legal Events

Date Code Title Description
FC Refusal